Dexketoprofen
As of the edition of 20 October 2026, Dexketoprofen is a small molecule: marketed, first approved in 1996 (ES); acts on PTGS1 and PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2000
- Kind
- Small molecule
- Brand name
- Enandol
- First approved
- 1 April 1996 (ES)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- A. Menarini GmbH; 3 holders in all
- Registered trials
- 30, 0 stopped early
- Disease areas
- Nervous system; Injuries; Bones, joints and muscles; Mouth and teeth; Chemically induced; Ear, nose and throat
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 10 | 9 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 3 | 2 | 0 | 0 |
| Phase 4 | 14 | 10 | 1 | 0 |
| All trials | 30 |